Media Relations News Releases Year: - Any -202120202019201820172016 Items per page 102550 Nov 7, 2017 Summary ToggleNovartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage Nov 6, 2017 Summary ToggleNovartis seeks leadership with Cosentyx® showing no radiographic progression in ankylosing spondylitis at 4 years Oct 30, 2017 Summary ToggleNovartis to present first of its kind evidence for Cosentyx® on potential to maintain mobility in patients with AS and PsA Oct 28, 2017 Summary ToggleNovartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a Sep 16, 2017 Summary ToggleNovartis’ Xolair® confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption Sep 13, 2017 Summary ToggleNovartis’ Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data Sep 7, 2017 Summary ToggleNovartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies Aug 30, 2017 Summary ToggleNovartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice Aug 27, 2017 Summary ToggleNovartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk Aug 27, 2017 Summary ToggleNovartis announces exploratory analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned Pagination First page First Previous page Previous … Page 7 Current page 8 Page 9 Page 10 … Next page Next Last page Last
